JP2023524853A - 改変されたｉＰＳＣ - Google Patents

改変されたｉＰＳＣ Download PDF

Info

Publication number
JP2023524853A
JP2023524853A JP2022568380A JP2022568380A JP2023524853A JP 2023524853 A JP2023524853 A JP 2023524853A JP 2022568380 A JP2022568380 A JP 2022568380A JP 2022568380 A JP2022568380 A JP 2022568380A JP 2023524853 A JP2023524853 A JP 2023524853A
Authority
JP
Japan
Prior art keywords
cell
cells
nucleic acid
pluripotent stem
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524853A5 (https=
Inventor
ガース ハミルトン
クリスティーヌ ザイドル
Original Assignee
アダプティミューン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプティミューン・リミテッド filed Critical アダプティミューン・リミテッド
Publication of JP2023524853A publication Critical patent/JP2023524853A/ja
Publication of JP2023524853A5 publication Critical patent/JP2023524853A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
JP2022568380A 2020-05-11 2021-05-11 改変されたｉＰＳＣ Pending JP2023524853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006903.5A GB202006903D0 (en) 2020-05-11 2020-05-11 Modified iPSCs
GB2006903.5 2020-05-11
PCT/GB2021/051125 WO2021229212A1 (en) 2020-05-11 2021-05-11 Modified ipscs

Publications (2)

Publication Number Publication Date
JP2023524853A true JP2023524853A (ja) 2023-06-13
JP2023524853A5 JP2023524853A5 (https=) 2024-04-19

Family

ID=71135035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568380A Pending JP2023524853A (ja) 2020-05-11 2021-05-11 改変されたｉＰＳＣ

Country Status (11)

Country Link
US (1) US20240016853A1 (https=)
EP (1) EP4149492A1 (https=)
JP (1) JP2023524853A (https=)
CN (1) CN115515606A (https=)
AU (1) AU2021271220A1 (https=)
BR (1) BR112022022654A2 (https=)
CA (1) CA3178047A1 (https=)
GB (1) GB202006903D0 (https=)
IL (1) IL298074A (https=)
MX (1) MX2022014116A (https=)
WO (1) WO2021229212A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2022714B1 (en) 2019-03-11 2020-09-18 Academisch Ziekenhuis Leiden Optimised RAG1 deficient SCID Gene Therapy
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
GB202111214D0 (en) * 2021-08-03 2021-09-15 Adaptimmune Ltd Modified ipscs
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN118421559B (zh) * 2024-07-04 2024-09-27 成都赛济元生物医药有限公司 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010148A1 (ja) * 2014-07-18 2016-01-21 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
JP2016525537A (ja) * 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター
JP2018533364A (ja) * 2015-10-30 2018-11-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
JP2019511236A (ja) * 2016-04-15 2019-04-25 メモリアル スローン ケタリング キャンサー センター トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法
JP2019513383A (ja) * 2016-04-08 2019-05-30 アダプティミューン・リミテッド Ｔ細胞受容体
US20190290694A1 (en) * 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194083B2 (en) * 2014-07-18 2025-01-14 Hiroshi Kawamoto Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
US12350312B2 (en) * 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525537A (ja) * 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター
WO2016010148A1 (ja) * 2014-07-18 2016-01-21 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
JP2018533364A (ja) * 2015-10-30 2018-11-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
JP2019513383A (ja) * 2016-04-08 2019-05-30 アダプティミューン・リミテッド Ｔ細胞受容体
JP2019511236A (ja) * 2016-04-15 2019-04-25 メモリアル スローン ケタリング キャンサー センター トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法
US20190290694A1 (en) * 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SANDERSON, JP ET AL.: "Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell", ONCOIMMUNOLOGY, vol. vol. 9(1), e1682381, JPN6025021738, 24 November 2019 (2019-11-24), pages 1 - 11, ISSN: 0005743324 *
YANG, J ET AL.: "Transgenic tools for analysis of the haematopoietic system: knock-in CD45 reporter and deletor mice", J IMMUNOL METHODS, vol. 337, JPN6025021737, 2008, pages 81 - 87, ISSN: 0005609019 *

Also Published As

Publication number Publication date
WO2021229212A1 (en) 2021-11-18
CA3178047A1 (en) 2021-11-18
AU2021271220A1 (en) 2022-12-22
CN115515606A (zh) 2022-12-23
BR112022022654A2 (pt) 2023-01-17
IL298074A (en) 2023-01-01
GB202006903D0 (en) 2020-06-24
MX2022014116A (es) 2022-12-08
US20240016853A1 (en) 2024-01-18
EP4149492A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP6884423B2 (ja) 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
JP2023524853A (ja) 改変されたｉＰＳＣ
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
JP2017505621A (ja) Ｔ細胞受容体を発現する細胞を生産する方法および組成物
JP2021512637A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
CN115885038A (zh) 表达嵌合抗原受体的免疫活性细胞
WO2018143454A1 (ja) 新規ｔ細胞受容体
TW202246511A (zh) 靶向ny-eso-1之增強免疫細胞療法
US20240392244A1 (en) Modification of cells with heterologous t-cell receptor (tcr) coding sequences
US20250228939A1 (en) Enhanced immune cell therapy
US20230374104A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
US20230019849A1 (en) Method for Preparing CD7-Negative, CD3-Positive T Cells
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202